

Appendix 4D

Half year report Period ending on 31 December 2008

PEPLIN, INC. ARBN 126 884 393

1. RESULTS FOR ANNOUNCEMENT TO THE MARKET

	Change	% Change	\$USD (000)
Revenues from ordinary activities and other income	down	52%	to 725
<i>Comments regarding above item:</i> Revenue from ordinary activities comprises government grants and interest earned on cash balances. A decrease in Australian based R&D activities has resulted in a decrease in grant revenue, and a decrease in interest rates on deposits has resulted in a decrease in interest income.			
Loss from ordinary activities after tax attributable to members	up	89%	to (22,849)
<i>Comments regarding above item:</i> Investment in research and development increased by US\$2.5 million to US\$12.1 million. This increase was primarily due to increases in our clinical trial costs, and in particular the continued expansion of our clinical development and regulatory affairs functions in our U.S. office. Sales, general and administration expenses also increased by US\$6.5 million to US\$10.6 million. This increase was due to an increase in our commercial costs as we move closer to commercialization of our products, as well as foreign exchange movements on our cash and debt facilities.			
Net Loss attributable to members	Up	89%	to (22,849)
Dividends (distributions)	It is not proposed to pay a dividend.		

2. REPORTING PERIOD

The financial information contained in this report is presented in US dollars for the **six month period ended 31 December 2008**.

Comparative amounts, unless otherwise indicated, are for the six month period ended 31 December 2007.

3. NET TANGIBLE ASSET BACKING PER SHARE

	31 Dec 2008	31 Dec 2007
Net tangible asset backing per share	US\$1.37	US\$2.59

4. CHANGES IN CONTROL OVER GROUP ENTITIES

During the half-year ended 31 December 2008 there were no changes in the control exercised by the company over group entities.

On 16 October 2008, the Company issued 819,378 shares of its common stock to acquire Neosil, a privately held, dermatology-focused company. Following the close of the transaction, Neosil became the Company's wholly-owned subsidiary. The results of operations of Neosil were included in the Company's financial statements from 16 October 2008.

5. DIVIDENDS AND DISTRIBUTIONS TO SHAREHOLDERS

During the half-year ended 31 December 2008 no dividends were either paid or proposed. The company does not operate a dividend reinvestment plan.

6. ASSOCIATES AND JOINT VENTURES

During the half-year the company did not hold any interests in associates or joint ventures.

7. UNAUDITED FINANCIAL INFORMATION

The information contained in this report is unaudited. The financial statements for the half-year ended 31 December 2008 have been reviewed by the company's auditors.



.....

David Smith
Company Secretary
13 February 2009